The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 trial of navitoclax and sorafenib in patients with refractory solid tumors with a hepatocellular carcinoma expansion cohort.
 
Oluwadunni Eunice Emiloju
Stock and Other Ownership Interests - Inovio Pharmaceuticals (I)
 
Jun Yin
Employment - Mayo Clinic; Moffitt Cancer Center
 
Emily Koubek
No Relationships to Disclose
 
Joel M. Reid
Consulting or Advisory Role - Elucida Oncology
 
Mitesh Borad
No Relationships to Disclose
 
Yanyan Lou
Consulting or Advisory Role - AstraZeneca; Janssen; Lilly; Turning Point Therapeutics
Research Funding - Blueprint Medicines (Inst); Daiichi-Sankyo (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Tolero Pharmaceuticals (Inst)
 
Mahesh Seetharam
Honoraria - AADi; Daiichi Sankyo; Deciphera; Horizon CME
Travel, Accommodations, Expenses - Horizon CME
 
Martin Joseph Edelman
Stock and Other Ownership Interests - Biomarker Strategies; Creatv MicroTech
Consulting or Advisory Role - BioAtla; BioAtla; Coherus Biosciences; Flame Biosciences; GE Healthcare; Kanaph Therapeutics; Sanofi/Regeneron; WindMIL
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Nektar (Inst); United Therapeutics (Inst); Windmil (Inst)
Patents, Royalties, Other Intellectual Property - Patent application for radiopharmaceutical to treat small cell lung cancer. (Inst)
Travel, Accommodations, Expenses - Nektar
Other Relationship - Anheart Therapeutics; AstraZeneca/MedImmune; Boehringer Ingelheim; Seagen; Takeda
 
Yixing Jiang
No Relationships to Disclose
 
Ahmed Omar Kaseb
Honoraria - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Research Funding - Adaptimmune (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Hengrui Pharmaceutical (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
 
James Posey
Consulting or Advisory Role - Lilly; Seagen
 
S. Lindsey Davis
Stock and Other Ownership Interests - Johnson & Johnson/MedTech
Speakers' Bureau - Allergan (I)
Research Funding - Boston Scientific (I); Bristol-Myers Squibb (Inst); EMD Serono (Inst); I-Mab (Inst); Merck (Inst); ORIC Pharmaceuticals (Inst); Symphogen (Inst); TriSalus Life Sciences (Inst); Tvardi Therapeutics (Inst)
 
Gregory J Gores
No Relationships to Disclose
 
Lewis R. Roberts
Honoraria - Focal Medical Communications; Kolkata Liver Meeting, Kolkata, India - Liver Foundation, West Bengal, India; Roche Kenya Limited, Nairobi, Kenya; Science First Communications Private Limited, Mumbai, India
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Clinical Care Options (Inst); Exact Sciences (Inst); Genentech (Inst); Global Life Sciences (Inst); GRAIL (Inst); Hepion Pharmaceuticals (Inst); Lynx Group (Inst); MedEd Design LLC (Inst); Medscape (Inst); Novartis Venture Fund (Inst); Pontifax (Inst); RedHill Biopharma (Inst); Roche (Inst); Roche (Inst); Roche Africa (Inst); TAVEC (Inst)
Speakers' Bureau - Bayer
Research Funding - ARIAD (Inst); BTG (Inst); Exact Sciences (Inst); Gilead Sciences (Inst); Glycotest (Inst); RedHill Biopharma (Inst); Wako Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - Five Prime Therapeutics. Royalties (Inst); Five Prime Therapeutics. Royalties.; US Patent No. 9,469,877: Materials and Methods for Diagnosis, Prognosis, Monitoring of Recurrence and Assessment of Therapeutic/Prophylactic Treatment of Pancreaticobiliary Cancer (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Naoko Takebe
No Relationships to Disclose
 
Andrea Elisabeth Wahner Hendrickson
Consulting or Advisory Role - Oxcia
Speakers' Bureau - OncLive
Research Funding - Amgen (Inst); ProLynx (Inst)
Patents, Royalties, Other Intellectual Property - TORL Therapeutics (Inst)
 
Scott H. Kaufmann
Consulting or Advisory Role - Attavare
Research Funding - Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Mayo Clinic holds a patent on an antibody developed in the Kaufmann laboratory. (Inst)
(OPTIONAL) Uncompensated Relationships - ProLynx
 
Joleen Hubbard
Consulting or Advisory Role - Bayer; BeiGene; Incyte; Merck; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Cardiff Oncology (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Pionyr (Inst); Roche (Inst); Seattle Genetics/Astellas (Inst); Senhwa Biosciences (Inst); Translational Research in Oncology (Inst); Treos Bio (Inst); Trovagene (Inst); Xilis (Inst)
 
Brian Addis Costello
Speakers' Bureau - Clinical Care Options/NCCN (Inst)
Research Funding - GlaxoSmithKline/Novartis (Inst)